Response to Comments: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis

Policy A59523 is a Response to Comments document for MolDX LCD L39467 addressing molecular biomarker testing to guide targeted therapy selection in rheumatoid arthritis. It records the comment period (10/06/2022–11/19/2022), the notice period start (08/31/2023), and the effective date (10/15/2023); the document itself does not contain specific coverage indications, limitations, documentation requirements, or frequency limits.

"This document is a Response to Comments for MolDX Local Coverage Determination L39467 (Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis); comment period 10/06..."

Sign up to see full coverage criteria, indications, and limitations.